期刊文献+

比阿培南研究进展 被引量:28

下载PDF
导出
摘要 比阿培南是一种较新的碳青霉烯类抗菌药物,抗菌谱广,抗菌活性强,临床用于治疗敏感菌引起的败血症、肺炎、肾盂肾炎、腹腔或妇科感染等,疗效显著。但由于该药的说明书较简单,相关参考资料较少,限制了其在临床的合理使用。根据比阿培南在临床使用中遇到的常见问题,例如在老年人、儿童、透析患者等特殊人群中应用的疗效及安全性,以及治疗不同病原菌、不同部位感染的给药方案设计等,该文综合中外文献,综述比阿培南的抗菌活性、药效/药动学特性及近些年的临床应用进展,旨在为该药的合理使用提供参考。
出处 《医药导报》 CAS 北大核心 2014年第3期352-354,共3页 Herald of Medicine
  • 相关文献

参考文献20

  • 1HARA T,ARAAKE M,WATABE H.Antibacterial activity of biapenem against recent clinical isolates[J].Jpn J Antibiot,2003,56(2):138-141.
  • 2YAMADA K,YAMAMOTO Y,YANAGIHARA K,et al.In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with pseudomonas aeruginosa[J].J Infect Chemother,2012,18(4):472-478.
  • 3刘文静,王瑶,刘勇,赵旺盛,孙自镛,倪语星,孙宏莉,徐英春,谢秀丽,王辉,陈民钧.比阿培南等3种碳青霉烯类抗生素的体外抗菌活性[J].中国感染与化疗杂志,2010,10(6):468-471. 被引量:29
  • 4赖艳榕,彭湘明,刘少娟,刘燕娣.比阿培南对鲍曼不动杆菌的抗菌活性评价[J].中国医药导报,2010,7(33):44-45. 被引量:7
  • 5THAMLIKITKUL V,TRAKULSOMBOON S.In vitro activity of biapenem against burkholderia pseudomallei[J].Int J Antimicrob Agents,2010,35(5):514-516.
  • 6NIIDA M,SAKAKIBARA S,KAWABATA T,et al.Combined effects of arbekacin with biapenem against in vitro and in vivo model of a mixture of MRSA and Pseudomonas aeruginosa[J].Jpn J Antibiot,2004,57(3):288-293.
  • 7冯彦来,文爱东,金鑫,丁莉坤,杨林.HPLC法测定人血浆中比阿培南的浓度及其药动学研究[J].中国药房,2011,22(14):1288-1290. 被引量:3
  • 8IKAWA K,MORIKAWA N,IKEDA K.Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients:a dosing strategy[J].Chemotherapy,2008,54(5):386-394.
  • 9SUMITANI Y,KOBAYASHI Y.Analysis on the effective dosage regimens for meropenem,biapenem and doripenem against P.aeruginosa infection based on pharmacokinetics and pharmacodynamics theory[J].Jpn J Antibiot,2007,60(6):394-403.
  • 10KAMEDA K,MIKI M,IKAWA K,et al.Dosing regimen rationalization of biapenem in pediatric patients:use of Monte Carlo simulation[J].Jpn J Antibiot,2009,62(1):1-8.

二级参考文献19

  • 1王金良.密切注视鲍曼不动杆菌的耐药发展趋势[J].中华检验医学杂志,2005,28(4):355-356. 被引量:194
  • 2刘成伟,涂植光,黄文祥,余登高,李崇智,郑行萍.比阿培南和亚胺培南对呼吸道和泌尿道致病菌的体外抗菌活性比较[J].中华检验医学杂志,2007,30(7):770-773. 被引量:14
  • 3Haluk V,Fatma B,Murat K,et al.High prevalence of OXA-51-type class D β-lactamases among ceftazidime-resistant clinical isolates of Aeinetobacter spp.:co-existence with OXA-58 in multiple centres[J].J Antimicrob Chemother,2006,58(3):537.
  • 4Chen HY,Livermore DM.In-vitro activity of biapenem,compared with imipenem and meropenem,against Pseudomonas acruginosa strains and mutants with known resistance mechanisms[J].J Antimicrob Chemother,1994,33(5):949-958.
  • 5Hirakata Y,Matsuda J,Mochida c,et al.Annual changes is susceptibility of clinical isolates to biapenem in Japanese[J].Jpn J Chemother,2002,50(6):329-351.
  • 6Hiraishi T,Miyata A,Hara T,et al.Bactericidal activity for biapenem against various bacteria[J].Jpn J Antibiot,2001,54(12):581.
  • 7Sirot D.Extend-spectrum plasmid-mediated β-lactamases[J].Jantimicrob Chemother,1995,36(Suppl A):19-34.
  • 8National Nosocomial Infections Surveillance system. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2000, issued June 2000[J]. Am J Infect Control,2004,32(8) :470-485.
  • 9PcryCM, Ibbotson T. Biapenem[J]. Drugs,2002,62(15): 2221-2234.
  • 10Luzzaro F, Enclimiani A, Docquier JI), et al. Prevalence and characterization of metallo-O-lactamases in clinical isolates of Pseudomonas aeruginosa[J].Diagn Microbiol Infect Dis, 2004,48(2) :131-135.

共引文献40

同被引文献228

引证文献28

二级引证文献147

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部